Tennis: the WTA imposes a test to determine the biological sex for the 2028 Olympics

The Women’s Tennis Association (WTA) has introduced mandatory genetic testing to determine biological sex for all female players ahead of the 2028 Olympic Games. The rule change, announced on July 21, requires all participants, players, officials, support staff, and accredited individuals, to undergo testing based on biological sex. This decision follows pressure from the International Olympic Committee (IOC), which aligned with U.S. President Donald Trump’s executive order from February 2025 excluding transgender athletes from women’s sports categories. The new policy mandates testing for the presence of the SRY gene, associated with male sexual development in mammals. Testing will involve a cheek swab, blood sample, or saliva collection, as determined by the WTA. The organization will cover the cost of these tests. If the result shows absence of the SRY gene, the athlete may compete in WTA tournaments. However, if the SRY gene is detected, the player will be barred from participating until further medical evaluation is conducted. Appeals and additional testing options are available. This move comes after several international sports federations, including World Boxing and World Athletics, implemented similar rules. The IOC’s alignment with the U.S. executive order led to its own eligibility criteria for female athletes competing in the 2028 Olympics in Los Angeles. As a result, the WTA sought to establish its own guidelines to ensure compliance with the broader regulatory framework. The testing process is set to begin in early August and must be completed before the start of the Games. It remains unclear whether the four Grand Slam tournaments, Australian Open, French Open, Wimbledon, and the U.S. Open, are subject to this requirement. These events are governed by the International Tennis Federation (ITF), which has stated it is aware of the WTA’s decision and will continue to work with stakeholders to ensure procedures align with the requirements for female athletes at the Olympics. The ITF emphasized its commitment to scientific data, fair competition, and the well-being of female players. Transgender athletes have historically been rare in professional tennis. The last known transgender woman to compete on the WTA circuit was Renée Richards, who played in the 1970s following a court ruling. Since then, there have been few instances of transgender athletes competing in the sport, highlighting the relatively limited impact of such cases on the WTA’s policies. The introduction of the genetic testing requirement has sparked debate among athletes, advocates, and officials. While some argue the policy ensures fairness and protects the integrity of women’s sports, others contend it infringes on individual rights and lacks sufficient scientific basis. The WTA maintains that the measure is necessary to uphold competitive equity and safeguard the interests of all participants. As the deadline for testing approaches, attention will focus on how the policy is implemented and its potential effects on both current and future athletes. The WTA has yet to release detailed information on how appeals will be processed or what specific medical evaluations will be required. For now, the focus remains on ensuring compliance with the new regulations ahead of the 2028 Olympics.